# MEDIFAST INC (MED)

Informational only - not investment advice.

CIK: 0000910329
SIC: 2090 Miscellaneous Food Preparations & Kindred Products
SIC breadcrumb: [Manufacturing](/division/D/) > [Food And Kindred Products](/major-group/20/) > [SIC 2090 Miscellaneous Food Preparations & Kindred Products](/industry/2090/)
Latest 10-K filed: 2026-02-17
SEC page: https://www.sec.gov/edgar/browse/?CIK=910329
Filing source: https://www.sec.gov/Archives/edgar/data/910329/000162828026008656/med-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-02-17 · accession 0001628280-26-008656 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000910329.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 385,788,000 USD | 2025 | verified |
| Net income | -18,672,000 USD | 2025 | verified |
| Assets | 247,973,000 USD | 2025 | verified |
| Free cash flow | 1,249,000 USD | 2025 | computed |
| Net margin | -4.84% | 2025 | computed |
| Operating margin | -3.68% | 2025 | computed |
| Revenue YoY | -35.96% | 2025 | computed |
| ROE | -9.39% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | MED | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | -4.8% | 5.3% | 12 | 51 |
| Operating margin | -3.7% | 7.6% | 17 | 49 |
| Revenue growth | -36.0% | 3.0% | 0 | 51 |
| FCF margin | 0.3% | 7.6% | 16 | 50 |
| ROE | -9.4% | 9.1% | 17 | 49 |
| ROA | -7.5% | 4.0% | 10 | 51 |
| Liabilities / equity | 0.25 | 1.19 | 4 | 49 |
| Current ratio | 4.69 | 1.65 | 98 | 51 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC major-group 20 Food And Kindred Products, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 385788000 | USD | 2025 | 2026-02-17 |
| Net income | -18672000 | USD | 2025 | 2026-02-17 |
| Assets | 247973000 | USD | 2025 | 2026-02-17 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-17. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000910329.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue |  |  |  |  |  |  |  | 1,526,087,000 | 1,598,577,000 | 1,072,054,000 | 602,463,000 | 385,788,000 |
| Net income |  |  | 17,835,000 | 27,721,000 | 55,789,000 | 77,916,000 | 102,859,000 | 164,031,000 | 143,568,000 | 99,415,000 | 2,091,000 | -18,672,000 |
| Operating income |  |  | 26,859,000 | 39,632,000 | 69,063,000 | 91,039,000 | 134,159,000 | 216,241,000 | 184,806,000 | 126,402,000 | 2,878,000 | -14,213,000 |
| Gross profit |  |  | 205,664,000 | 227,812,000 | 379,899,000 | 536,858,000 | 697,815,000 | 1,127,597,000 | 1,140,414,000 | 775,850,000 | 444,623,000 | 275,187,000 |
| Diluted EPS |  |  | 1.49 | 2.29 | 4.62 | 6.43 | 8.68 | 13.89 | 12.73 | 9.10 | 0.19 | -1.70 |
| Operating cash flow |  |  | 25,350,000 | 43,237,000 | 60,816,000 | 84,261,000 | 145,196,000 | 94,545,000 | 194,570,000 | 147,657,000 | 24,476,000 | 6,863,000 |
| Capital expenditures |  |  | 2,876,000 | 3,242,000 | 4,940,000 | 10,058,000 | 5,887,000 | 34,209,000 | 16,681,000 | 6,483,000 | 7,454,000 | 5,614,000 |
| Dividends paid |  |  | 11,889,000 | 15,390,000 | 23,160,000 | 35,396,000 | 53,190,000 | 63,856,000 | 71,620,000 | 73,017,000 | 715,000 | 195,000 |
| Share buybacks | 33,894,000 | 10,516,000 |  |  | 29,995,000 | 33,114,000 | 5,000,000 | 55,999,000 | 126,445,000 | 3,602,000 | 0.00 | 0.00 |
| Assets |  |  | 121,216,000 | 145,929,000 | 169,429,000 | 194,653,000 | 276,084,000 | 398,326,000 | 316,213,000 | 309,908,000 | 284,213,000 | 247,973,000 |
| Liabilities |  |  | 25,200,000 | 37,348,000 | 60,323,000 | 89,821,000 | 118,838,000 | 195,852,000 | 161,169,000 | 108,427,000 | 74,104,000 | 49,053,000 |
| Stockholders' equity |  |  | 96,016,000 | 106,563,000 | 109,106,000 | 104,832,000 | 157,246,000 | 202,474,000 | 155,044,000 | 201,481,000 | 210,109,000 | 198,920,000 |
| Cash and cash equivalents |  |  | 52,436,000 | 75,077,000 | 81,364,000 | 76,974,000 | 163,723,000 | 104,183,000 | 87,691,000 | 94,440,000 | 90,928,000 | 89,303,000 |
| Free cash flow |  |  | 22,474,000 | 39,995,000 | 55,876,000 | 74,203,000 | 139,309,000 | 60,336,000 | 177,889,000 | 141,174,000 | 17,022,000 | 1,249,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin |  |  |  |  |  |  |  | 10.75% | 8.98% | 9.27% | 0.35% | -4.84% |
| Operating margin |  |  |  |  |  |  |  | 14.17% | 11.56% | 11.79% | 0.48% | -3.68% |
| Return on equity |  |  | 18.58% | 26.01% | 51.13% | 74.32% | 65.41% | 81.01% | 92.60% | 49.34% | 1.00% | -9.39% |
| Return on assets |  |  | 14.71% | 19.00% | 32.93% | 40.03% | 37.26% | 41.18% | 45.40% | 32.08% | 0.74% | -7.53% |
| Liabilities / equity |  |  | 0.26 | 0.35 | 0.55 | 0.86 | 0.76 | 0.97 | 1.04 | 0.54 | 0.35 | 0.25 |
| Current ratio |  |  | 4.15 | 3.37 | 2.41 | 1.94 | 2.10 | 1.81 | 1.58 | 2.43 | 3.34 | 4.69 |

## As-reported value updates

1 tracked difference above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

Ledger: /company/MED/revisions/


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-03. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000910329.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-09-30 |  |  | 3.27 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | 3.67 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  |  | 2.77 | reported discrete quarter |
| 2023-Q3 | 2023-06-30 |  | 30,280,000 |  | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 235,869,000 |  | 2.12 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 191,015,000 | 6,035,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 174,739,000 | 8,316,000 | 0.76 | reported discrete quarter |
| 2024-Q2 | 2024-03-31 |  | 8,316,000 |  | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 168,558,000 |  | -0.75 | reported discrete quarter |
| 2024-Q3 | 2024-06-30 |  | -8,154,000 |  | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 140,163,000 |  | 0.10 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 119,003,000 | 801,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 115,728,000 | -772,000 | -0.07 | reported discrete quarter |
| 2025-Q2 | 2025-03-31 |  | -772,000 |  | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 105,555,000 |  | 0.22 | reported discrete quarter |
| 2025-Q3 | 2025-06-30 |  | 2,480,000 |  | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 89,409,000 |  | -0.21 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 75,096,000 | -18,119,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 76,044,000 | -2,122,000 | -0.19 | reported discrete quarter |
| 2026-Q2 | 2026-03-31 |  | -2,122,000 |  | reported discrete quarter |
| 2026-Q2 | 2026-06-30 | 76,384,000 |  | -0.28 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from MED's latest 10-K: [/company/MED/business/](/company/MED/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from MED's latest 10-K: [/company/MED/risk-factors/](/company/MED/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/910329/000162828026051928/med-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary.
Confidence: high
Filing date: 2026-08-03
Report date: 2026-06-30

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Note Regarding Forward-Looking Statements

Certain information in this report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Act”). Forward-looking statements generally can be identified by use of phrases or terminology such as “intend,” “anticipate,” “expect,” or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals, or targets contained herein are also considered forward-looking statements. These statements are based on the current expectations of our management of Medifast and are subject to certain events, risks, uncertainties, and other factors. These risks and uncertainties include, but are not limited to, those described in our 2025 Form 10-K and those described from time to time in our future reports filed with the SEC. Although Medifast believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this report. All of the forward-looking statements contained herein speak only as of the date of this report. We undertake no obligation to update any information contained in this report or to publicly release the results of any revisions to forward-looking statements to reflect events or circumstances of which we may become aware after the date of this report.

The following discussion should be read in conjunction with the unaudited condensed consolidated financial statements and related notes appearing elsewhere herein.

Overview

Medifast, Inc. (“Medifast,” the “Company,” “we” or “us”) is the health and wellness company known for its science-backed, comprehensive metabolic health system. In October 2025, Medifast announced its strategic transformation, unveiling its focus on holistic metabolic health. The Company started 2026 by moving from transformation to execution, leveraging its extensive experience in structured weight loss coupled with recent scientific research and enhanced product offerings to address the needs of a broader metabolic health market. In July 2026, Medifast announced the launch of Trilivy, a comprehensive metabolic health system uniquely designed to support healthy lifestyle change. The transition from OPTAVIA® to a new brand with the launch of Trilivy represents an evolution of the company’s vision, platform, and purpose, expanding beyond traditional weight

16

Table of Contents

loss to address the broader metabolic health challenges impacting more than 90% of U.S. adults today. Medifast’s approach focuses on addressing the root cause of metabolic dysfunction. This strategic shift targets a larger and what is believed to be a more sustainable market, focusing on a long-term growth strategy intended to guide the Company over the next decade by aligning science, products, and coaching with increasing demand for new solutions as awareness of metabolic dysfunction grows.

This growth strategy will initially be focused on improving coach productivity and expanding our coach network. We operate a well-capitalized business with a powerful lifestyle solution and a business model that has impacted over 3 million lives and, for the quarter ended June 30, 2026, had a network of approximately 11,700 active earning independent coaches. Medifast stands at the forefront of evidence-based wellness solutions, and its coach-first model creates significant opportunities for coaches’ individual businesses. This is designed to create a “flywheel effect” as new clients join, driving coach productivity, which in turn attracts new active earning coaches, leading to even more new clients and further productivity.

The Company offers a simple, yet comprehensive approach to achieving optimal metabolic health and well-being by empowering individuals to make lasting changes. Through the dedicated support of our coaches, approximately 90% of whom were clients first, our clients are guided through every step of their wellness journey.

Our scientifically developed products and habit creation framework, reinforced by coaches and community support, provide proven health benefits and serve as a promising foundation to develop a comprehensive metabolic health system. We continuously innovate and build upon our scientific and clinical heritage to fulfill our mission of lifelong transformation, through metabolic science and human connectionTM. Coaches provide unparalleled support along with community, nutrition, and healthy habits. In a world where health and well-being can often be a difficult and solitary journey, our comprehensive system offers intensely personalized support to individuals seeking to transform their health. The goal of this holistic approach is to empower people to master their metabolic health and improve body composition, beginning with a quality weight loss journey and offering the flexibility to achieve it on their own terms. At the heart of the metabolic health system is a powerful three-part delivery model that helps individuals build healthier habits, unlock their potential and achieve optimal metabolic health:

Independent Coaches & Community: Coaches provide individualized support and guidance to clients on their path to optimal metabolic health and well-being and a community of like-minded individuals offer real-time connection and support.

The Habits of Health Transformational System: A proprietary system that provides easy steps toward a sustainable healthy lifestyle.

Science & Products: Clinically proven plans and scientifically developed products, backed by dietitians, scientists, and physicians.

In October 2025, the Company introduced Metabolic Synchronization® — a breakthrough science that reverses metabolic dysfunction through a targeted reset of the body’s metabolism. Research demonstrates that the Company's comprehensive system improves metabolic health by activating strong and targeted fat burn (i.e., by reducing bad visceral fat), preserving lean mass, and protecting muscle.1 This approach results in healthy, quality weight loss that extends beyond the scale, ultimately empowering individuals to achieve their health goals.

Metabolic health, often misunderstood or overlooked, refers to the body’s ability to efficiently convert food into energy and regulate critical bodily functions. Metabolic dysfunction is a state that can often go unnoticed, placing strain on the body’s metabolic processes and potentially leading to serious health challenges.

Science has always been integral to Medifast’s identity. Through ongoing research and compelling data that elevate the science behind the Company’s plans and innovative products, the Company is energizing its coach community to empower individuals to take control of their metabolic health. In July 2026, the company introduced the Trilivy Reset Fueling line, enhanced with MetaVantage Technology™, which further supports metabolic health by helping reduce waist circumference while also supporting normal fat metabolism and healthy insulin function.2 We expect to bring the updated product line fully to market this quarter. These upcoming innovations are expected to further strengthen the Company’s offerings to help clients achieve optimal metabolic health.

1 In a clinical study, individuals on the Company's 5 & 1 Plan experienced a reduction of 14% visceral fat and 98% of lean mass was retained at 16 weeks. Arterburn, L.M., C.D. Coleman, J. Kiel, et al. Randomized controlled trial assessing two commercial weight loss programs in adults with overweight or obesity. Obes Sci Pract 2019; 5/1: 3-14.

2 Pedret, A., R.M. Valls, L. Calderon-Perez, et al. Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial. Int J Obes (Lond). 2019;43(9):1863- 1868. doi: 10.1038/s41366-018-0220-0.

17

Table of Contents

While GLP-1 medication usage continues to accelerate, medication alone may not be adequate for achieving sustainable, long-term health outcomes without the integration of comprehensive lifestyle modifications, nutritional guidance, and behavioral support. Recent research indicates that approximately one-third of users discontinue the medication after six months, and up to 74% stop after a year.3 Furthermore, studies show that two-thirds of weight lost on GLP-1 medications is typically regained within 12 months of stopping treatment, with cardiometabolic benefits often reversing as well.4 GLP-1 medications can be effective tools, but lasting results require more than just medication—they demand holistic behavior change.

The need for change extends beyond the obesity epidemic, as over 90% of Americans are metabolically unhealthy,5 impacting biomarkers of poor health, energy regulation, and weight management. Healthy, quality weight loss that prioritizes burning fat while preserving muscle is essential for improving metabolic health but it demands commitment, consistency, and support. Given that GLP-1 medications are shown to be most effective when combined with lifestyle changes, we see strong alignment with our expertise in helping people create durable habits through coach-supported, behavior-based systems. Our experience in guiding individuals towards change through habit-based systems, supported by a coach, is highly compatible with the demonstrated effectiveness of these medications when paired with lifestyle modifications.

In addition to coach support, by focusing on the root causes of metabolic dysfunction, Medifast is seeking to unlock new opportunities to reach and empower individuals at every stage of their health journey. For those utilizing weight loss medications, Medifast’s programs are intended to provide complementary solutions to enhance metabolic function and overall health.

Regardless of their need states, our integrated, coach-supported, lifestyle-based approach helps clients achieve their health goals. Coaches introduce clients to a set of healthy habits, often beginning with healthy eating, alongside exclusive products and plans. These offerings are a key component that supports the Company’s mission and helps clients to build and sustain healthy habits in their lives.

Finding new clients and reactivating former clients remains an important area of focus for our business and our coaches. We believe our coach-based model is scalable, drives both client success and growth, and represents a key competitive advantage. The coaching model is anchored on clients’ needs, helping place them into supportive and energized health and wellness communities that share similar challenges and goals. With a coach, clients successfully lost 10 times more weight and 17 times more fat than those attempting to lose weight on their own.6 Coaches deliver highly tailored and personalized support and motivation, sharing their passion for healthy living and lifestyle transformation. Despite their diverse geographies and backgrounds, our coaches form a tight-knit community that supports, encourages, and inspires one another.

Our coaches are independent contractors, not employees, who support clients and market our products and services to friends, family, and other people in their communities, primarily through word-of-mouth, email, and social media channels including Facebook, Instagram, X (formerly known as Twitter), and video conferencing platforms. Products are shipped directly to clients; coaches do not handle or deliver products. This model enables our coaches to focus on client support

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/910329/000162828026008656/med-20251231.htm
Complete FY 2025 MD&A: /company/MED/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary.
Confidence: high
Filing date: 2026-02-17
Report date: 2025-12-31

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. Our significant accounting policies are described in Note 2 to the consolidated financial statements.

The preparation of our consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Management develops, and changes periodically, these estimates and assumptions based on historical experience and on various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. Management considers the following accounting policies to be the most critical in preparing our consolidated financial statements. These critical accounting policies have been discussed with our Audit Committee, as appropriate.

Revenue Recognition: Our revenue is derived primarily from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other healthy living products. Revenue is recognized upon delivery to the shipping carrier and net of discounts, rebates, promotional adjustments, price adjustments, allocated consideration to loyalty programs, and estimated returns.

Our performance obligations are satisfied at a point in time. Revenue from products transferred to customers at a point in time accounted for substantially all of our revenue for the years ended December 31, 2025, 2024, and 2023.

Our return policy allows for customer returns of consumable products from the time of order until 30 days following the date of receipt, and upon our authorization. We adjust revenues for the products expected to be returned and a liability is recognized for expected refunds to customers. We estimate expected returns based on historical levels and project this experience into the future.

Our sales contracts may give customers the option to purchase additional products priced at a discount. Options to acquire additional products at a discount can come in many forms, such as customer reward programs and incentive offerings including pricing arrangements, and promotions.

We reduce the transaction price for customer reward programs and certain incentive offerings including pricing arrangements, promotions, and incentives that represent variable consideration and separate performance obligations. The Company allocates consideration between the initial sale of products and the customer reward program and incentive offering. The Company discontinued its reward program in July 2025.

Amounts billed to customers for shipping and handling activities are treated as a promised service performance obligation and are recorded as revenue in our Consolidated Statements of Operations upon fulfillment of the performance obligation. Shipping and handling costs incurred by the Company for the delivery of products to customers are considered a cost to fulfill the contract and are included in cost of sales in our Consolidated Statements of Operations.

We expense coach compensation and credit card fees during the period in which the corresponding revenue is earned. These costs are recorded in selling, general and administrative expense in our Consolidated Statements of Operations.

Long-lived Asset Impairment: Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset.

Income Taxes: Deferred tax assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

33

Table of Contents

The benefit of a tax position is recognized in the consolidated financial statements in the period during which, based on all available evidence, management believes it is more-likely-than-not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in our Consolidated Balance Sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

Our policy is to recognize interest and penalties accrued on uncertain tax positions as part of income tax expense.

BACKGROUND

Medifast (NYSE: MED) is the health and wellness company known for its science-backed, coach-guided lifestyle system. Designed to help address the challenges of metabolic dysfunction, the Company’s holistic approach integrates personalized plans, scientifically developed products and a framework for habit creation — all supported by a dedicated network of independent coaches. Driven to improve metabolic health through advanced science and comprehensive behavioral support, Medifast has introduced Metabolic Synchronization™, a breakthrough science that reverses metabolic dysfunction through a targeted reset of the body’s metabolism. Research shows the Company’s comprehensive system activates strong and targeted fat burn to enhance metabolic health and body composition by reducing visceral fat, preserving lean mass and protecting muscle. Backed by more than 40 years of clinical heritage, Medifast continues to advance its mission of Lifelong Transformation, Making Healthy Lifestyle Second Nature. Our product sales accounted for approximately 96.4%, 96.8% and 97.5% of our revenues in each of 2025, 2024, and 2023, respectively. We review and analyze a number of key operating and financial metrics to manage our business, including the number of active earning coaches and average quarterly revenue generated per active earning coach. The number of active earning coaches decreased by approximately 40.6% to 16,100 for the quarter ended December 31, 2025 from the quarter ended December 31, 2024, and the average revenue per active earning coach was increased 6.2% to $4,664 for the quarter ended December 31, 2025 from the quarter ended December 31, 2024.

Our OPTAVIA business unit accounted for all of our revenues for each the years ended 2025, 2024 and 2023. We have operated and reported as a single sales segment, OPTAVIA, since 2018. By maintaining our commitment to building capabilities in the areas that matter most to our coaches and clients within the OPTAVIA channel, we believe our strong financial foundation, flexible model and variable cost structure coupled with disciplined growth initiatives position Medifast for the current environment and the future.

34

Table of Contents

CONSOLIDATED RESULTS OF OPERATIONS - 2025 COMPARED TO 2024

The following table reflects our Consolidated Statements of Operations for the years ended December 31, 2025 and 2024 (in thousands, except percentages):

[[GREPCENT_TABLE]]
[["","2025","","2024","","$ Change","","% Change"],["Revenue","$","385,788","","$","602,463","","$","(216,675)","","(36.0)%"],["Cost of sales","110,601","","157,840","","(47,239)","","(29.9)%"],["Gross profit","275,187","","444,623","","(169,436)","","(38.1)%"],["Selling, general, and administrative","289,400","","441,745","","(152,345)","","(34.5)%"],["Income (loss) from operations","(14,213)","","2,878","","(17,091)","","(593.8)%"],["Other income"],["Interest income","5,516","","4,804","","712","","14.8","%"],["Other income (expense)","3,058","","","(3,895)","","","6,953","","","178.5%"],["","8,574","","909","","7,665","","843.2","%"],["Income (loss) before provision for income taxes","(5,639)","","3,787","","(9,426)","","(248.9)%"],["Provision for income taxes","13,033","","1,696","","11,337","","668.5%"],["Net income (loss)","$","(18,672)","","$","2,091","","$","(20,763)","","(993.0)%"],["% of revenue"],["Gross profit","71.3%","","73.8%"],["Selling, general, and administrative","75.0%","","73.3%"],["Income (loss) from operations","(3.7)%","","0.5%"]]
[[/GREPCENT_TABLE]]

Revenue: Revenue decreased $216.7 million, or 36.0%, to $385.8 million in 2025 from $602.5 million in 2024. The year-over-year decline in revenue was primarily driven by a decrease in the number of active earning coaches. The total number of active earning coaches for the three months ended December 31, 2025 decreased to 16,100 from 27,100 for the corresponding period in 2024, a decrease of 40.6%. The number of active earning coaches has been trending downward year-over-year since the first quarter of 2023. The decrease in the number of active earning coaches was driven by continued pressure with client acquisition reflecting broader challenges in the operating environment, including rapid adoption of GLP-1 medications for weight loss. The average revenue per active earning coach increased 6.2% to $4,664 for the three months ended December 31, 2025 from $4,391 for the three months ended December 31, 2024. The increase in the revenue per active earning coach for the quarter was driven by greater alignment of our network of coaches, prioritizing productive coaches and efficient coach network structures.

Costs of sales: Cost of sales decreased $47.2 million, or 29.9%, to $110.6 million in 2025 from $157.8 million in 2024. The decrease in cost of sales was primarily driven by an approximately $54.9 million decrease due to lower sales volumes and a $2.6 million decrease due to restructuring of external manufacturing agreements that did not recur in 2025, partially offset by $8.0 million of loss of leverage on fixed costs and $3.0 million of inventory reserves which are primarily related to the reformulation of the Essential product line.

Gross profit: In 2025, gross profit decreased $169.4 million, or 38.1%, to $275.2 million from $444.6 million in 2024. The decrease in gross profit was primarily attributable to lower revenue. As a percentage of sales, gross profit decreased 250 basis points to 71.3% for 2025 from 73.8% for 2024 primarily driven by the loss of leverage on fixed costs.

Selling, general and administrative: Selling, general and administrative (“SG&A”) expenses were $289.4 million in 2025, a decrease of $152.3 million, or 34.5%, as compared to $441.7 million in 2024, primarily due to a $85.1 million decrease in

35

Table of Contents

coach compensation due to lower sales volumes and a decrease in the number of active earning coaches, a $13.4 million decrease in company-led marketing related expenses, a $12.5 million decrease for supply chain optimization that did not

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/MED/mda/fy2025/
All MD&A years: /company/MED/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/MED/mda/fy2024/): filed 2025-02-18; accession 0001628280-25-006094 (https://www.sec.gov/Archives/edgar/data/910329/000162828025006094/med-20241231.htm)
- [FY 2023 MD&A](/company/MED/mda/fy2023/): filed 2024-02-20; accession 0001628280-24-005620 (https://www.sec.gov/Archives/edgar/data/910329/000162828024005620/med-20231231.htm)
- [FY 2022 MD&A](/company/MED/mda/fy2022/): filed 2023-02-21; accession 0001628280-23-004341 (https://www.sec.gov/Archives/edgar/data/910329/000162828023004341/med-20221231.htm)
- [FY 2021 MD&A](/company/MED/mda/fy2021/): filed 2022-02-23; accession 0001628280-22-003534 (https://www.sec.gov/Archives/edgar/data/910329/000162828022003534/med-20211231.htm)




## Macro cross-references

Indicators mapped to this company's SIC classification (industry 2090 Miscellaneous Food Preparations & Kindred Products) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index
- [TCU](/indicator/TCU/): Capacity Utilization: Total Index
- [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm

Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/MED.md · JSON record: /company/MED.json · verified financials: /company/MED/financials.json / /company/MED/financials.csv · machine TOC for the whole site: /llms.txt